DERMATOMYOSITIS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Dermatomyositis is a rare condition that causes muscle inflammation. It presents with symmetric proximal muscle weakness, skin rash, and extra macular manifestations such as esophageal dysfunction and interstitial lung disease. Dermatomyositis is strongly associated with malignancy, especially in adults. Dermatomyositis is a systemic disorder that most frequently affects the skin and muscles but may also affect the joints, the esophagus, the lungs, and less commonly, the heart. Dermatomyositis presents with characteristic skin findings and symmetric proximal skeletal muscle weakness. It can also affect other organ systems such as the pulmonary, cardiovascular, and gastrointestinal systems. Various factors cause dermatomyositis such as genetic factors, immunologic factors, and environmental factors such as infections, drugs, and radiation.

Furthermore, there are three types of dermatomyositis namely, Adult Dermatomyositis, Dermatomyositis Sine Myositis, and Juvenile (Childhood) Dermatomyositis (JDMS). Dermatomyositis Sine Myositis is a term used to describe patients who are present with the dermatological features of dermatomyositis but an absence of associated muscle findings. Juvenile (childhood) dermatomyositis (JDMS) is an early onset form of dermatomyositis (DM), a systemic, autoimmune inflammatory muscle disorder with vasculopathy, characterized by proximal and symmetrical muscle weakness, evocative skin lesions, and systemic manifestations.

Market Dynamics

Market players are involved in the development of novel treatment for dermatomyositis which is expected to propel the market growth over the forecast period. For instance, in May 2022, Kezar Life Sciences, Inc., a clinical-stage biotechnology company, announced result from the PRESIDIO Phase 2 clinical trial of zetomipzomib (KZR-616) in patients with dermatomyositis (DM) and polymyositis (PM). The results of the PRESIDIO trial showed that most DM and PM patients saw clinically meaningful improvements in total improvement score (TIS).

Key features of the study

• This report provides an in-depth analysis of the global dermatomyositis market, market size (USD Mn), and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global dermatomyositis market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
• Key companies covered as a part of this study include AstraZeneca Plc., Bristol-Myers Squibb Company, Octapharma AG, Corbus Pharmaceuticals Holdings, Inc., CSL Limited, Ermium Therapeutics, Kezar Life Sciences Inc., Mallinckrodt Plc., Néovacs, Horizon Therapeutics plc., and Pfizer Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global dermatomyositis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dermatomyositis market

Dermatomyositis Market Segmentation

• By Type (Revenue, USD Mn, 2020 - 2033)
  • Adult Dermatomyositis
  • Dermatomyositis Sine Myositis
  • Juvenile (Childhood) Dermatomyositis (JDMS)
• By Treatment Type Insights (Revenue, USD Mn, 2020 - 2033)
  • Anti-inflammatory Medication
  • Immunosuppressive Drugs
  • Immunoglobulin
  • Others (Plasma Exchange, Monoclonal antibody among others)
• By Distribution Channel Insights (Revenue, USD Mn, 2020 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region Insights (Revenue, USD Mn, 2020 - 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East & Africa
    • GCC Countries
    • Israel
    • Rest of Middle East & Africa
• Key Players
  • AstraZeneca Plc.
  • Bristol-Myers Squibb Company
  • Octapharma AG
  • Corbus Pharmaceuticals Holdings, Inc.
  • CSL Limited
  • Ermium Therapeutics
  • Kezar Life Sciences Inc.
  • Mallinckrodt Plc.
  • Néovacs, Horizon Therapeutics plc.
  • Pfizer Inc.